Akari Therapeutics PLC (NASDAQ:AKTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, October 17th.
According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “
AKTX has been the topic of a number of other reports. Canaccord Genuity reissued a “buy” rating and issued a $15.00 price objective (down from $33.00) on shares of Akari Therapeutics PLC in a research note on Monday, June 26th. ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th. William Blair raised shares of Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a research note on Friday, September 22nd. Finally, Chardan Capital reissued a “neutral” rating and issued a $2.50 price objective (down from $6.00) on shares of Akari Therapeutics PLC in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. Akari Therapeutics PLC has a consensus rating of “Hold” and an average price target of $8.00.
Akari Therapeutics PLC (AKTX) traded down $0.10 on Tuesday, hitting $4.15. 193,566 shares of the company were exchanged, compared to its average volume of 418,632. Akari Therapeutics PLC has a 1-year low of $3.18 and a 1-year high of $22.20.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/akari-therapeutics-plc-aktx-downgraded-to-sell-at-zacks-investment-research/1722047.html.
A hedge fund recently raised its stake in Akari Therapeutics PLC stock. VHCP Management II LLC lifted its holdings in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 15.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 426,297 shares of the biopharmaceutical company’s stock after purchasing an additional 56,807 shares during the period. Akari Therapeutics PLC accounts for 0.8% of VHCP Management II LLC’s holdings, making the stock its 13th biggest holding. VHCP Management II LLC owned about 3.62% of Akari Therapeutics PLC worth $1,965,000 as of its most recent SEC filing. Institutional investors own 27.03% of the company’s stock.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with our FREE daily email newsletter.